文献速递MDS 与骨髓增殖性肿瘤血栓与止血贫血与红细胞疾病

血栓与出血对老年骨髓增生异常综合征患者生存的影响:人群分析

Impact of thrombosis and bleeding on survival of older people with myelodysplastic syndromes: a population analysis.
PubMed 文献 · J Thromb Haemost · 2026-01-07

VTE与<3个月和3-6个月死亡风险增加相关,但6个月后无显著关联;出血在所有事件后时间段均与死亡风险增加相关。病例交叉分析证实出血的关联,但提示VTE可能存在未测量混杂。

要点

  • 出血事件后各时间段死亡风险均升高,<3个月HR 4.25。
  • VTE后<3个月死亡风险升高(HR 3.21),但6个月后无显著关联。
  • 需制定策略降低老年MDS患者的出血风险。

核心结论

  • 出血与MDS患者后续死亡风险增加相关,VTE的风险可能受未测量混杂影响。

主要发现

  • VTE与<3个月死亡风险增加相关(HR 3.21;95% CI 2.84-3.62),3-6个月HR 1.51(95% CI 1.23-1.85),6-12个月HR 1.18(95% CI 0.98-1.42),>12个月HR 1.00(95% CI 1.91-1.11)。
  • 出血与<3个月死亡风险增加相关(HR 4.25;95% CI 3.89-4.65),3-6个月HR 2.11(95% CI 1.82-2.45),6-12个月HR 1.60(95% CI 1.39-1.85),>12个月HR 1.43(95% CI 1.31-1.57)。
  • 病例交叉分析证实出血的关联,但提示VTE存在潜在未测量混杂。

关键数值与推荐

  • VTE和出血事件通过验证算法识别,并作为时变协变量建模。
  • Cox回归调整年龄、性别、种族、NCI合并症指数和SEER-Medicare MDS风险评分。

临床怎么用

  • 临床应重视老年MDS患者的出血风险评估与管理,以改善生存。

局限性

  • VTE与死亡风险的关联可能受未测量混杂因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombotic and bleeding complications in myelodysplastic syndromes (MDS) can affect therapy, but how they impact overall survival remains unclear. OBJECTIVES: Evaluating the impact of venous thromboembolism (VTE) and bleeding on survival in older MDS patients. METHODS: Incident MDS cases were collected from the Surveillance, Epidemiology, and End Results Medicare database (2007-2017) and followed from diagnosis until death. Baseline demographics, comorbidities, and the Surveillance, Epidemiology, and End Results Medicare MDS Risk Score were assessed. VTE and bleeding events were identified using validated algorithms and modeled as time-varying covariates. Cox regression, adjusted for age, sex (male vs female), race, National Cancer Institute Comorbidity Index, and Surveillance, Epidemiology, and End Results Medicare MDS Risk Score, estimated the hazard ratio (HR) for death. RESULTS: Among 13 995 MDS patients (median age, 82 years; 46% female), 1114 VTE and 1905 bleeding events occurred. VTE was associated with increased mortality within <3 months (HR, 3.21; 95% CI, 2.84-3.62) and 3 to 6 months (HR, 1.51; 95% CI, 1.23-1.85), but not for 6 to 12 months (HR, 1.18; 95% CI, 0.98, 1.42) or >12 months (HR, 1.00; 95% CI, 1.91, 1.11). Bleeding was associated with mortality for all postevent time periods assessed: <3 months (HR, 4.25; 95% CI, 3.89, 4.65), 3 to 6 months (HR, 2.11; 95% CI, 1.82, 2.45), 6 to 12 months (HR, 1.60; 95% CI, 1.39, 1.85), and >12 months (HR, 1.43; 95% CI, 1.31, 1.57). Case-crossover analysis confirmed these associations for bleeding but revealed potential unmeasured confounders for VTE. CONCLUSION: Bleeding was associated with subsequent mortality in MDS patients. For VTE, this risk seems to be affected by potential unmeasured confounders. These findings underscore the need for strategies to mitigate bleeding risk in this population.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Gergi M, Sparks A, Zakai NA, et al. Impact of thrombosis and bleeding on survival of older people with myelodysplastic syndromes: a population analysis. J Thromb Haemost. 2026. PMID: 41512964. doi:10.1016/j.jtha.2025.11.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。